// App-Quantinova.ai

905 : Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 EMERGE Study

Researchers

Presenter

  • Andre Goy

Principal Investigators

  • Rajni Sinha

  • Michael E. Williams

  • Sevgi Kalayoglu Besisik

  • Johannes Drach

  • Radhakrishnan Ramchandren

  • Michael J. Robertson

  • Irit Avivi

  • Jacob M. Rowe

  • Raoul Herbrecht

  • Achiel Van Hoof

  • Miklos Egyed

  • Lei Zhang

  • Sherri Cicero

  • Tommy Fu

  • Thomas E. Witzig

Medical Centers

  • Shaare Zedek Medical Center, Jerusalem, Israel

  • Istanbul Bilim University School of Medicine, Istanbul, Turkey

  • Oncology and Hematology, Hopital de Hautepierre, Strasbourg, France

  • Rambam Medical Center, Haifa, Israel

  • Department of Internal Medicine, Kaposi Mor Teaching Hospital, Kaposvar, Hungary

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Medical University of Vienna, Vienna, Austria

  • General Hospital St-Jan, Brugge, Belgium

Locations

  • Austria

  • Turkey

  • United States

  • Israel

  • France

  • Belgium

  • Hungary

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Deep vein thrombosis

  • Hodgkin's Lymphoma

  • Pulmonary embolism

  • Thrombocytopenia

  • Neutropenia

  • Non‐Hodgkin Lymphoma

  • Venous thrombosis

  • Lymphomas

  • Anemia

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Lenalidomide

  • Mitoxantrone

  • Bortezomib

  • Rituximab

Outcome

  • N/A

Study Design

  • open label

  • single arm

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved